Corrigendum to S.O. 4062(E) dated 8.11.2019, W.r.t M/s Torrent Pharmaceuticals Ltd.

## Report on Amendment to National Pharmaceutical Pricing Authority Notification S.O. 4062E **1. Executive Summary:** This report analyzes an amendment to the National Pharmaceutical Pricing Authority's (NPPA) notification S.O. 4062E, dated 08.11.2019, regarding the fixation of retail price. The core purpose of this amendment is to correct a manufacturer's name associated with a specific entry (Sl. No. 6) in the table of the original notification. Key findings reveal a simple but crucial correction from "Ms Akums Drugs and Pharmaceuticals Limited" to "Ms Torrent Pharmaceuticals Limited," ensuring accurate record-keeping and compliance. **2. Introduction:** This report aims to provide a comprehensive understanding of the amendment published by the Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, concerning a correction to the NPPA's notification S.O. 4062E, based solely on the provided text. **3. Policy Overview:** * **Original Policy:** The amendment references and modifies the NPPA's notification S.O. 4062E, dated 08.11.2019, related to the "fixation of retail price" of pharmaceuticals. * **Core Objective(s):** The original policy (S.O. 4062E) aims to regulate pharmaceutical pricing, specifically the "fixation of retail price". The amendment seeks to maintain the accuracy and validity of the retail price data. **4. Background and Rationale:** The amendment appears to be a necessary correction to address a factual error in the original notification. The likely reason for this specific amendment is to rectify an incorrect manufacturer's name associated with Sl. No. 6 in the table of the original notification. This correction is crucial for ensuring accurate tracking of retail pricing responsibilities and avoiding potential legal or regulatory complications. **5. Key Provisions / Changes:** * **Specific Part Changed:** The amendment directly targets the "name of the manufacturer mentioned in column no. 5 for the Sl. No. 6" in the table within the original notification S.O. 4062E. * **New Rule/Provision:** The amendment stipulates that the manufacturer's name for Sl. No. 6 "is to be henceforth, read as Ms Torrent Pharmaceuticals Limited instead of Ms Akums Drugs and Pharmaceuticals Limited." * **Difference/Effect of the Change:** The change ensures that Ms Torrent Pharmaceuticals Limited is correctly identified as the manufacturer associated with Sl. No. 6, replacing the previously incorrectly listed Ms Akums Drugs and Pharmaceuticals Limited. This rectification is intended to ensure accurate information is recorded, prevent misattribution of responsibilities, and maintain data integrity. **6. Target Audience and Stakeholders:** Based on the provided text, the target audience and stakeholders directly affected by these changes include: * The National Pharmaceutical Pricing Authority (NPPA). * Ms Torrent Pharmaceuticals Limited. * Ms Akums Drugs and Pharmaceuticals Limited. * Other pharmaceutical manufacturers subject to retail price regulations. * Entities involved in the pharmaceutical supply chain. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The NPPA is the primary responsible agency, as it issued the original notification and the subsequent amendment. The Department of Pharmaceuticals within the Ministry of Chemicals and Fertilizers also plays a role in overseeing the NPPA. The Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi and Controller of Publications, Delhi are responsible for uploading and publishing the gazette. * **Timelines/Procedures:** The amendment is effective immediately from the date of publication (June 3, 2025). The text does not specify any further procedures beyond the correction itself. The note regarding "Uploaded by Dte. of Printing..." suggests that the implementation involves updating official records and disseminating the corrected information. * **Changes Specific Implementation:** The most crucial implementation aspect is ensuring all relevant internal databases and public records maintained by the NPPA and other stakeholders are updated to reflect the corrected manufacturer name for Sl. No. 6 of the original notification's table. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of this specific change is to: * Ensure accurate record-keeping of pharmaceutical manufacturers linked to specific retail price fixations. * Prevent any potential confusion or legal issues arising from incorrect manufacturer attribution. * Maintain the integrity and reliability of the NPPA's pricing data. * Enable better compliance monitoring and enforcement. **9. Conclusion:** The amendment to the NPPA's notification S.O. 4062E, dated 08.11.2019, represents a crucial correction that ensures the accuracy of manufacturer information related to retail price fixation. While seemingly minor, this change is vital for maintaining regulatory integrity, facilitating accurate compliance, and ensuring transparency within the pharmaceutical pricing system. The amendment underscores the importance of meticulous record-keeping and prompt correction of errors in regulatory documents.

Key Entities Referenced